VIMOVO

Kraj: Izrael

Język: angielski

Źródło: Ministry of Health

Składnik aktywny:

ESOMEPRAZOLE AS MAGNESIUM TRIHYDRATE 20 MG; NAPROXEN 500 MG

Dostępny od:

ASTRA ZENECA ISRAEL LTD

Kod ATC:

G02CC02

Forma farmaceutyczna:

TABLETS MODIFIED RELEASE

Droga podania:

PER OS

Wyprodukowano przez:

ASTRA ZENECA AB., SWEDEN

Grupa terapeutyczna:

NAPROXEN

Wskazania:

Vimovo is a combination product that contains naproxen and esomeprazole. It is indicated for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers. Vimovo is not recommended for initial treatment of acute pain because the absorption of naproxen is delayed compared to absorption from other naproxen-containing products.

Data autoryzacji:

2011-12-01